2016
DOI: 10.2147/ijn.s110525
|View full text |Cite
|
Sign up to set email alerts
|

Synergistic locoregional chemoradiotherapy using a composite liposome-in-gel system as an injectable drug depot

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
3
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(6 citation statements)
references
References 44 publications
0
3
0
Order By: Relevance
“…Intravesical liposome-in-gel systems have been developed to enhance drug retention in the bladder while reducing systemic levels, presenting a promising approach for intravesical applications [58]. Similarly, liposome-in-gel-paclitaxel systems have been investigated for regional delivery in chemoradiotherapy, resulting in increased cytotoxicity and reduction in tumor volume [59].…”
Section: Drug Deliverymentioning
confidence: 99%
See 1 more Smart Citation
“…Intravesical liposome-in-gel systems have been developed to enhance drug retention in the bladder while reducing systemic levels, presenting a promising approach for intravesical applications [58]. Similarly, liposome-in-gel-paclitaxel systems have been investigated for regional delivery in chemoradiotherapy, resulting in increased cytotoxicity and reduction in tumor volume [59].…”
Section: Drug Deliverymentioning
confidence: 99%
“…Injectable hydrogels have gained popularity as versatile platforms for drug delivery due to their gelation upon injection, which enables localized and sustained drug release [4,55,56,60,63,64,[73][74][75][76][77][78]80,103]. Achieving targeted and localized drug delivery to specific sites, such as tumor cells or pathological areas, has been a major focus of research, and various strategies have been explored to achieve this objective [40,41,59,62,73,75,77].…”
Section: Perspectivementioning
confidence: 99%
“…[57] Also beta-lapachone-loaded polymer implants were used for the treatment of prostate cancer. [58] Other applications have included, composite liposome-in-gel systems as injectable drug depots, [59] injectable in situ formation of carboxymethyl chitin hydrogel implants for 3D cell culture, [60] PLGA based DOX-loaded implants for local DOX release, [61] poly(D,L-lactide-co-glycolide)-based methotrexateloaded implants for enhanced anti-tumor efficacy against sarcoma 180, [62] paclitaxel-loaded injectable in situ-forming gels, [63] and injectable in situ-forming hydrogels for osteogenic differentiation of human turbinate mesenchymal stem cells. [64] An advanced hydrogel based on self-assembling peptides tethered with RADA16-GGQQLK (QLK) and RADA16-GGLRK-KLGKA (LRK) sequences was synthesized to promote the formation of capillary-like tubular endothelial structures, as well as supporting the survival of the embedded cells.…”
Section: Hydrogels For Local (In Situ) Administrationmentioning
confidence: 99%
“…On the other hand, the encapsulated liposomes act as drug pockets with enhanced stability, leading to a more sustained and prolonged drug release comparatively than that found for conventional liposomes [ 39 , 40 , 41 , 42 ] or native hydrogel matrices [ 25 ]. Liposomal hydrogel delivery systems have shown improved efficiency for the treatment of several inflammatory diseases [ 43 ] and chemotherapy [ 44 , 45 ] comparatively to conventional therapies, ascribed to their ability to provide longer-term and in situ release of the target therapeutic compound, minimizing the toxic side effects due to drug leakage.…”
Section: Introductionmentioning
confidence: 99%